Citigroup Inc Tg Therapeutics, Inc. Put Options Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 12, 2024	BUY	$13.32 - $19.19 $466,200 - $671,650	35,000 Added 87.72%	74,900 $1.33 Million
Q1 2024 May 10, 2024	SELL	$13.02 - $21.3 $65,100 - $106,500	-5,000 Reduced 11.14%	39,900 $606,000
Q4 2023 Feb 09, 2024	BUY	$6.68 - $18.81 $97,528 - $274,626	14,600 Added 48.18%	44,900 $766,000
Q3 2023 Nov 09, 2023	SELL	$8.36 - $26.5 $112,859 - $357,750	-13,500 Reduced 30.82%	30,300 $253,000
Q2 2023 Aug 10, 2023	BUY	$15.48 - $35.0 $678,024 - $1.53 Million	43,800 New	43,800 $1.09 Million
Q4 2022 Feb 09, 2023	BUY	$5.01 - $11.83 $299,598 - $707,434	59,800 New	59,800 $707,000
Q4 2021 Feb 10, 2022	BUY	$15.2 - $35.51 $4.56 Million - $10.7 Million	300,000 New	300,000 $5.7 Million

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.